OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion clinical trials

Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)

This study is looking at two medicines, nivolumab and ipilimumab, for people with advanced bladder cancer that can’t be removed by surgery. It wants to see if these medicines can help keep the cancer from growing after initial chemotherapy.